2023-01-25T07:06:10-06:00 2022-06-30 WithumSmithBrown PC ONE TOWER CENTER BLVD 14TH FL EAST BRUNSWICK NJ 08816 990 2021-07-01 843043384 Mission Cure Inc % MEGAN GOLDEN MISS 4013752873 c/o Megan Golden 245 W 107th 15A New York NY 10025 MEGAN GOLDEN PRESIDENT/CEO 4013752873 2022-11-15 true MEGAN GOLDEN 999009999 Brad Caruso P01249134 7328281614 2 2021 2023-03-07 01:45:13Z X MEGAN GOLDEN c/o Megan Golden 245 W 107th11B New York NY 10025 724152 false X mission-cure.org X 2019 DE THE MISSION OF THE CORPORATION IS TO IMPROVE THE LIVES OF PEOPLE SUFFERING FROM UNSOVLED DISEASES THROUGH PATIENT ENGAGEMENT, INNOVATIVE FINANCING, EDUCATION, AND RESEARCH 4 4 0 10 0 950164 724152 0 0 55 0 -17500 -18000 932719 706152 0 50000 0 0 194037 326021 0 0 17954 67564 75920 261601 451941 671118 254211 672489 940800 1371 15471 671118 925329 MISSION:CURE IS A PATIENT-LED COALITION OF PATIENTS, RESEARCHERS, DOCTORS, AND ENTREPRENEURS PIONEERING A NEW APPROACH TO IMPROVING THE LIVES OF PEOPLE SUFFERING FROM PANCREATITIS AND OTHER DISEASES. MISSION:CURE COLLABORATES WITH IMPACT INVESTORS AND HEALTHCARE PAYERS TO DISCOVER LIFE-ALTERING THERAPIES AND BRING THEM TO PATIENTS. false false 395566 50000 The Organization's major programs consist of developing therapies, engagement communities and improving care (see Schedule O). 395566 true true false false false false false false false false false false false false false false false false false false false false false false true false false true false false false false false false false false false false true false false false false false false false false false 2 0 true 0 false false false false false false false false false false false false false X 4 4 false false false false false false false true true false false true true true true true true true true false CA NY X MEGAN GOLDEN 4013752873 245 W 107TH ST APT 11B New York NY 10025 Megan Golden President and CEO 40.0 0.0 X X 67904 0 0 Linda Martin Board Chairperson 8.0 0.0 X X 0 0 0 Mickey Levitan Treasurer 2.0 0.0 X X 0 0 0 Bruce Bloom Secretary 2.0 0.0 X X 0 0 0 67904 0 0 0 false false false 0 161143 563009 55145 724152 0 0 0 0 0 0 0 0 0 161143 18000 -18000 -18000 0 0 0 0 0 0 0 706152 -18000 50000 50000 0 0 0 82500 65020 15780 1700 0 210654 210654 0 0 0 8825 8745 80 24042 22780 1262 0 0 15005 15005 0 0 0 46491 34945 820 10726 1580 70 646 864 5186 522 4664 2764 51 2713 0 0 3301 3301 0 0 0 0 0 1593 1593 451941 395566 38421 17954 595406 906061 0 0 67000 34000 0 0 0 0 0 0 0 0 0 0 10083 739 0 0 0 0 0 0 0 0 0 0 0 0 672489 940800 1371 15471 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1371 15471 X 454118 716329 217000 209000 671118 925329 672489 940800 254211 X true false true X 0 0 0 950164 724152 1674316 0 0 0 0 0 950164 724152 1674316 531809 1142507 0 0 0 1674316 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED Ian Lindsay Live LLC 3216 14th Avenue S Seattle WA 98144 LIVE EVENT false 18000 18000 GALA 161143 161143 18000 0 161143 161143 18000 18000 -18000 true Johns Hopkins Hospital 3910 Keswick Rd Bldg No 4300A Baltimore MD 21211 520591656 501(C)(3) 50000 Pancreatitis Research Pilot 1 Schedule I, Part I, Line 2 The Organization provides grants to further its mission. Formal grant agreements are approved and signed by the CEO. Grants have milestones and performance requirements which are closely monitored by the Organization. Reports are required to be submitted and are reviewed by the Organization. Future funding is contingent upon satisfaction of requirements in the grant. X 3 51546 FMV X Crypto Currency 1 3599 Market Value false true true Schedule M Part I Line (b) The amount reported on Part I Line B represents the number of contributions. Schedule M, Part I, Line 32a THE ORGANIZATION UTILIZES A THIRD PARTY TO PROCESS CRYPTO CURRENCY AND DIGITAL ASSET DONATIONS AND HANDLE THE TAX COMPLIANCE REQUIREMENTS. THE GIFTS ARE CONVERTED INTO CASH, AND THE ORGANIZATION DOES NOT TAKE DIRECT POSSESSION OF ANY CRYPTOCURRENCY. FORM 990 Responses Form 990 Part III, Line 4 - Program Services 1. Developing therapies a. Advocated with more than 6 life sciences companies to pursue therapies for pancreatitis; provided information to support drug development b. Supported launch of Johns Hopkins Pancreatitis Pain Research Program, conducting research to identify the most effective treatments for pancreatitis patients' pain c. Worked with UK-based biotech Healx to understand chronic pancreatitis and identify and test therapeutic compounds d. Conducted inventory of animal models of pancreatitis and validated measures for outcomes important to patients 2.Engaging communities a. Reached over 39,000 patients, caregivers, clinicians, and scientists with website and over 5,000 people with educational videos b. Translated entire website into Spanish, including patient education materials c. Developed and disseminated new educational content about nutrition, pain management, and the patient experience 3. Improving care a. Collaborated with Johns Hopkins University to launch Johns Hopkins Pancreatitis Pain Research Program to effectively treat pancreatitis pain. b. Surveyed patients in partnership with two academic medical centers to determine symptoms and conditions that co-occur with chronic pancreatitis and may be related c. Completed "Best Practices" for pancreatitis care, reviewed by experts d. Developed a model for a virtual center of excellence that provides outcome-based, coordinated care FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION PROVIDES A DRAFT COPY OF FORM 990 FOR THE BOARD TO REVIEW PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C Mission: Cure is committed to avoiding conflicts of interests or the appearance of such conflicts that may call into question the integrity of the organization and its work. There are two primary situations that give rise to conflicts or the appearance of conflicts: when Mission: Cure employees have relationships with parties that do business with Mission: Cure (and in particular, when they give or accept gifts from such parties), and when Mission: Cure employees participate in outside activities that relate to, draw upon or compete with the work of Mission: Cure. In addition, certain contracts have prohibitions on the parties with whom you may do business. Conflict of interest situations are often complex, and you must consult Executive Director before engaging in such activity. FORM 990, PART VI, SECTION B, LINE 13: Mission: Cure will investigate any suspected fraudulent or dishonest use or misuse of Mission: Cure's resources or property by staff, board members, consultants or volunteers. Mission: Cure is committed to maintaining the highest standards of conduct and ethical behavior and promotes a working environment that values respect, fairness and integrity. All staff, board members and volunteers shall act with honesty, integrity and openness in all their dealings as representatives for the organization and comply with all applicable laws and regulations. Failure to follow these standards will result in disciplinary action including possible termination of employment, dismissal from one's board or volunteer duties and possible civil or criminal prosecution if warranted. FORM 990, PART VI, SECTION B, LINE 15: COMPENSATION PROCESS FOR TOP OFFICIAL: THE ORGANIZATION USES THE DEPARTMENT OF LABOR STATISTICS AND SALARY GUIDE TO OBTAIN COMPARABLE DATA ON POSITIONS. FURTHERMORE, THE ORGANIZATION PERIODICALLY REVIEW THE COMPENSATION ARRANGEMENTS AND BENEFITS TO ENSURE THAT THEY ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION AND THE RESULT OF ARM'S LENGTH BARGAINING. FORM 990, PART IV, SECTION C, LINE 19B GOVERNING DOCUMENTS, DISCLOSURE EXPLANATION, THE FINANCIAL STATEMENTS, AND OTHER DOCUMENTS, SUCH AS THE CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990 PART IX LINE 11G DESCRIPTION:OTHER FEES TOTAL FEES:46491